Preliminary programme ECNP Consultation Meeting, 8-10 March 2009, Nice, France

Biomarkers and experimental medicine in developing new treatments in neuropsychopharmacology

Sunday 8 March – Introduction to biomarkers	(start programme incl. buffet dinner)
---	---------------------------------------

Chairs: Christine Gispen-de Wied, the Netherlands Guy Goodwin, United Kingdom

19.00 Buffet open

19.15 Welcome and introduction Guy Goodwin United Kingdom

19.30 Biomarkers; setting the scene: industry

Orest Hurko

USA

20.00 Biomarkers; setting the scene: CHMP Karl Broich

Germany

20.30 Deserts and coffee

20.45 Discussion

21.45 Close

Monday 9 March - Biomarkers and Experimental medicine

Chairs: Christine Gispen-de Wied, the Netherlands David Nutt, United Kingdom

09.00 Selecting responsive sub-groups by diagnostic Lars Vedel Kessing markers in depression Denmark

09.30 Selecting responsive sub-groups by diagnostic Wim van den Brink markers in addiction The Netherlands

10.00 Discussion

10.30 Break

11.00 Selecting responsive sub-groups by diagnostic

Andreas Meyer-Lindenberg

markers in schizophrenia Germany

11.30 Selecting responsive sub-groups by diagnostic Guy Goodwin markers in bipolar disorder United Kingdom

12.00 Discussion

12.30 Lunch

13.30 Proof of concept studies in psychiatry: industry Emilio Merlo-Pich

Italy

14.00	Efficacy markers in animals: anxiolytics	Sven Ove Ögren Sweden
14.30	Efficacy markers in man: anxiolytics	Herman Westenberg
15.00	Теа	The Netherlands
13.00	Tod	
15.30	Efficacy markers in animals: depression	Michel Hamon France
16.00	Efficacy markers in man: depression	Catherine Harmer United Kingdom
16.30	Regulatory status of efficacy markers	Fernando de Andres-Trelles Spain
17.00	Discussion	
18.00	Close	
Tuesday 10 March – Experimental medicine		
Chairs	:Christine Gispen-de Wied, the Netherlands Guy Goodwin, United Kingdom	
08.30	Efficacy markers in animals: schizophrenia	Mark Geyer USA
09.00	Efficacy markers in man: schizophrenia	Bill Deakin United Kingdom
09.30	PET and investigation of brain neurobiology	Gitte Moos Knudsen Denmark
10.00	Break	
10.30	Getting the dose right and dose response: antipsychotics	Ilan Rabiner United Kingdom
11.00	Getting the dose right and dose response: antidepressants	Jeffrey Meyer Canada
11.30	Discussion	
12.30	Lunch	
13.30	Experimental medicine and early drug development: what do we need from the regulators?	Gersham Dent USA
14.00	Discussion	
15.00	Close	